KURA Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Kura Oncology's net margin of --. Kura Oncology's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Kura Oncology has a consensus price target of --, signalling upside risk potential of 217.11%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 258.97%. Given that Armata Pharmaceuticals has higher upside potential than Kura Oncology, analysts believe Armata Pharmaceuticals is more attractive than Kura Oncology.

Kura Oncology has a beta of 0.746, which suggesting that the stock is 25.385% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.301%.

Kura Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Kura Oncology quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Kura Oncology's net income of -$54.4M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, Kura Oncology's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology is -- versus 706.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Kura Oncology's net margin of --. Kura Oncology's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Kura Oncology has a consensus price target of --, signalling upside risk potential of 217.11%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Kura Oncology, analysts believe Perspective Therapeutics is more attractive than Kura Oncology.

Kura Oncology has a beta of 0.746, which suggesting that the stock is 25.385% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Kura Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Kura Oncology quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Kura Oncology's net income of -$54.4M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Kura Oncology's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology is -- versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of -- compared to Kura Oncology's net margin of 47.23%. Kura Oncology's return on equity of -- beat Halozyme Therapeutics's return on equity of 156.62%.

Kura Oncology has a consensus price target of --, signalling upside risk potential of 217.11%. On the other hand Halozyme Therapeutics has an analysts' consensus of $64.13 which suggests that it could grow by 36.64%. Given that Kura Oncology has higher upside potential than Halozyme Therapeutics, analysts believe Kura Oncology is more attractive than Halozyme Therapeutics.

Kura Oncology has a beta of 0.746, which suggesting that the stock is 25.385% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.555%.

Kura Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Kura Oncology quarterly revenues are --, which are smaller than Halozyme Therapeutics quarterly revenues of $290.1M. Kura Oncology's net income of -$54.4M is lower than Halozyme Therapeutics's net income of $137M. Notably, Kura Oncology's price-to-earnings ratio is -- while Halozyme Therapeutics's PE ratio is 15.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology is -- versus 6.43x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Kura Oncology's net margin of 18.02%. Kura Oncology's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Kura Oncology has a consensus price target of --, signalling upside risk potential of 217.11%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 695.46%. Given that Protalix BioTherapeutics has higher upside potential than Kura Oncology, analysts believe Protalix BioTherapeutics is more attractive than Kura Oncology.

Kura Oncology has a beta of 0.746, which suggesting that the stock is 25.385% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Kura Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Kura Oncology quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Kura Oncology's net income of -$54.4M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Kura Oncology's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology is -- versus 3.03x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.